Summit Therapeutics Inc.
SMMT
$18.95
$0.291.55%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -19.37% | -24.71% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -13.21% | -3.96% | |||
| Operating Income | 13.21% | 3.96% | |||
| Income Before Tax | 13.57% | 5.44% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 13.57% | 5.44% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 13.57% | 5.44% | |||
| EBIT | 13.21% | 3.96% | |||
| EBITDA | 13.21% | 3.97% | |||
| EPS Basic | 14.58% | 8.27% | |||
| Normalized Basic EPS | 14.55% | 8.31% | |||
| EPS Diluted | 14.58% | 8.27% | |||
| Normalized Diluted EPS | 14.55% | 8.31% | |||
| Average Basic Shares Outstanding | 1.18% | 3.09% | |||
| Average Diluted Shares Outstanding | 1.18% | 3.09% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||